Calliditas Therapeutics AB (publ)

DB:LC8A Stock Report

Market Cap: €11.2b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Calliditas Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Renee Aguiar-Lucander

Chief executive officer

SEK 18.4m

Total compensation

CEO salary percentage36.6%
CEO tenure7.4yrs
CEO ownershipn/a
Management average tenure3.6yrs
Board average tenureless than a year

Recent management updates

Recent updates

CEO Compensation Analysis

How has Renee Aguiar-Lucander's remuneration changed compared to Calliditas Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-SEK 480m

Mar 31 2024n/an/a

-SEK 525m

Dec 31 2023SEK 18mSEK 7m

-SEK 466m

Sep 30 2023n/an/a

-SEK 451m

Jun 30 2023n/an/a

-SEK 292m

Mar 31 2023n/an/a

-SEK 393m

Dec 31 2022SEK 13mSEK 6m

-SEK 412m

Sep 30 2022n/an/a

-SEK 628m

Jun 30 2022n/an/a

-SEK 608m

Mar 31 2022n/an/a

-SEK 576m

Dec 31 2021SEK 11mSEK 5m

-SEK 500m

Sep 30 2021n/an/a

-SEK 452m

Jun 30 2021n/an/a

-SEK 600m

Mar 31 2021n/an/a

-SEK 501m

Dec 31 2020SEK 7mSEK 3m

-SEK 433m

Sep 30 2020n/an/a

-SEK 286m

Jun 30 2020n/an/a

-SEK 198m

Mar 31 2020n/an/a

-SEK 54m

Dec 31 2019SEK 4mSEK 3m

-SEK 33m

Sep 30 2019n/an/a

-SEK 54m

Jun 30 2019n/an/a

-SEK 35m

Mar 31 2019n/an/a

-SEK 136m

Dec 31 2018SEK 4mSEK 2m

-SEK 132m

Compensation vs Market: Renee's total compensation ($USD1.77M) is below average for companies of similar size in the German market ($USD5.09M).

Compensation vs Earnings: Renee's compensation has increased whilst the company is unprofitable.

CEO

Renee Aguiar-Lucander (62 yo)

7.4yrs

Tenure

SEK 18,367,000

Compensation

Ms. Renee Aguiar-Lucander serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief Executive Officer of Calliditas Therapeutics AB (publ) since May 2017. Prior to joining...

Leadership Team

NamePositionTenureCompensationOwnership
Renee Aguiar-Lucander
Chief Executive Officer7.4yrsSEK 18.37mno data
Fredrik Johansson
Chief Financial Officer7.2yrsno data0%
€ 0
Lars Stubberud
Vice President of Technical Operations1.8yrsno datano data
Asa Hillsten
Head of IR & Sustainability1.8yrsno datano data
Brian Gorman
Group General Counsel1.8yrsno datano data
Sandra Frithiof
Vice President of Human Resources4.8yrsno datano data
Ann-Kristin Myde
Head of Clinical Development & VP of Project Management7.8yrsno datano data
Richard Philipson
Chief Medical Officer4.3yrsno datano data
Teona Johnson
Head of US Marketing3.6yrsno datano data
David Ferraro
Head of US Sales3.6yrsno datano data
Monika Tornsen
President of North Americaless than a yearno datano data
Christopher Ngai
Vice President of Market Accessno datano datano data

3.6yrs

Average Tenure

49yo

Average Age

Experienced Management: LC8A's management team is considered experienced (3.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yoshikazu Aoki
Non-Executive Directorless than a yearno datano data
Mark Hensley
Chairmanless than a yearno datano data
Jonathan Barratt
Member of Scientific Advisory Boardno datano datano data
Jürgen Floege
Member of Scientific Advisory Boardno datano datano data
Richard Lafayette
Member of Scientific Advisory Boardno datano datano data
Brad Rovin
Member of Scientific Advisory Boardno datano datano data
Vladimir Tesar
Member of Scientific Advisory Boardno datano datano data
Hérnan Trimarchi
Member of Scientific Advisory Boardno datano datano data
Masaya Etoh
Non-Executive Directorless than a yearno datano data
Heather Reich
Member of Scientific Advisory Boardno datano datano data
Hong Zhang
Member of Scientific Advisory Boardno datano datano data

0.08yrs

Average Tenure

Experienced Board: LC8A's board of directors are not considered experienced ( 0.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/10/14 08:54
End of Day Share Price 2024/09/30 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Calliditas Therapeutics AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingird GafanhãoBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Erik HultgårdCarnegie Investment Bank AB